Brokerages Anticipate Fibrocell Science Inc (FCSC) to Announce -$0.41 Earnings Per Share
Equities research analysts expect Fibrocell Science Inc (NASDAQ:FCSC) to post ($0.41) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Fibrocell Science’s earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.50). Fibrocell Science posted earnings of ($0.36) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 13.9%. The business is scheduled to report its next earnings report on Thursday, November 2nd.
On average, analysts expect that Fibrocell Science will report full-year earnings of ($2.30) per share for the current fiscal year, with EPS estimates ranging from ($2.58) to ($2.02). For the next year, analysts expect that the company will post earnings of ($1.13) per share, with EPS estimates ranging from ($1.23) to ($1.02). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Fibrocell Science.
Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.31).
FCSC has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $5.70 price target on shares of Fibrocell Science in a research note on Friday, June 9th. ValuEngine raised shares of Fibrocell Science from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th. Zacks Investment Research raised shares of Fibrocell Science from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Wednesday, July 12th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $7.00 price target (up from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Fibrocell Science has an average rating of “Hold” and a consensus price target of $5.21.
Fibrocell Science (FCSC) traded down 0.98% on Wednesday, hitting $3.02. The stock had a trading volume of 91,541 shares. The company’s market cap is $44.45 million. Fibrocell Science has a 52-week low of $1.57 and a 52-week high of $4.64. The stock’s 50-day moving average is $2.97 and its 200-day moving average is $2.79.
An institutional investor recently raised its position in Fibrocell Science stock. Creative Planning grew its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,090 shares of the company’s stock after buying an additional 48,755 shares during the quarter. Creative Planning owned 0.42% of Fibrocell Science worth $245,000 as of its most recent filing with the Securities & Exchange Commission. 54.70% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/04/brokerages-anticipate-fibrocell-science-inc-fcsc-to-announce-0-41-earnings-per-share.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.